Teva Pharmaceutical Industries Ltd.
TEVA Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, revenue was flat, EPS fell 296.0%, free cash flow grew 121.4% and total debt fell 3.69%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow TEVA
Teva Pharmaceutical Industries Ltd. (TEVA) EV/Sales
As of 16 October 2026, Teva Pharmaceutical Industries Ltd. (TEVA) trades at a EV/Sales of 3.5×. Over the past ten years it has ranged from 1.8× (October 2023) to 3.9× (September 2016); the current reading is higher than 99% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and in line with the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.8× | 19.16% |
| FY2024 | 2.4× | 32.23% |
| FY2023 | 1.8× | (7.25%) |
| FY2022 | 1.9× | 3.82% |
| FY2021 | 1.9× | (9.16%) |
| FY2020 | 2.1× | (2.37%) |
| FY2019 | 2.1× | (10.11%) |
| FY2018 | 2.3× | 3.15% |
| FY2017 | 2.3× | (29.42%) |
| FY2016 | 3.2× | 7.15% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.0× | 10.07% |
| Mar 2026 | 2.7× | (3.13%) |
| Dec 2025 | 2.8× | 26.12% |
| Sep 2025 | 2.3× | 9.14% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VTRS Viatris Inc. compare | 2.3× |
| RDY Dr. Reddy's Laboratories Ltd compare | 2.9× |
| TAK Takeda Pharmaceutical Co. compare | 3.0× |
| ELAN Elanco Animal Health Incorporated compare | 3.0× |
| HLN Haleon PLC Sponsored ADR compare | 3.1× |
| TEVA Teva Pharmaceutical Industries Ltd. | 3.5× |
| NBIX Neurocrine Biosciences, Inc. compare | 4.1× |
| ZTS Zoetis Inc. compare | 4.4× |
| UTHR United Therapeutics Corporation compare | 6.5× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)